BNTX - Understanding BioNTech's Position In Biotechnology Industry Compared To Competitors | Benzinga
In the ever-evolving and intensely competitive business landscape, conducting a thorough company analysis is of utmost importance for investors and industry followers. In this article, we will carry out an in-depth industry comparison, assessing BioNTech (NASDAQ:BNTX) alongside its primary competitors in the Biotechnology industry. By meticulously examining key financial metrics, market positioning, and growth prospects, we aim to offer valuable insights to investors and shed light on company's performance within the industry.
BioNTech Background
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies; cell therapies; bispecific antibodies; and small-molecule immunomodulators. BioNTech is partnered with several large pharmaceutical companies, including Roche, Eli Lilly, Pfizer, Sanofi, and Genmab. COVID-19 vaccine Comirnaty is its first commercialized product.
| Company | P/E | P/B | P/S | ROE | EBITDA (in billions) | Gross Profit (in billions) | Revenue Growth |
|---|---|---|---|---|---|---|---|
| BioNTech SE | |||||||
| 8.67 | |||||||
| 1.17 | |||||||
| 3.57 | |||||||
| 0.81% | |||||||
| $0.27 | |||||||
| $0.24 | |||||||
| -74.13% | |||||||
| AbbVie Inc | |||||||
| 42.08 | |||||||
| 22.42 | |||||||
| 4.94 | |||||||
| 14.25% | |||||||
| $4.74 | |||||||
| $7.44 | |||||||
| -5.97% | |||||||
| Amgen Inc | |||||||
| 19.81 | |||||||
| 19.47 | |||||||
| 5.58 | |||||||
| 23.97% | |||||||
| $3.6 | |||||||
| $5.1 | |||||||
| 3.77% | |||||||
| Vertex Pharmaceuticals Inc | |||||||
| 30.27 | |||||||
| 6.29 | |||||||
| 10.87 | |||||||
| 6.47% | |||||||
| $1.23 | |||||||
| $2.16 | |||||||
| 6.39% | |||||||
| Gilead Sciences Inc | |||||||
| 17.03 | |||||||
| 4.44 | |||||||
| 3.66 | |||||||
| 10.03% | |||||||
| $3.23 | |||||||
| $5.49 | |||||||
| 0.11% | |||||||
| Regeneron Pharmaceuticals Inc | |||||||
| 24.19 | |||||||
| 3.71 | |||||||
| 7.37 | |||||||
| 4.12% | |||||||
| $1.23 | |||||||
| $2.93 | |||||||
| 14.53% | |||||||
| Biogen Inc | |||||||
| 25.02 | |||||||
| 2.52 | |||||||
| 3.66 | |||||||
| -0.47% | |||||||
| $0.05 | |||||||
| $1.87 | |||||||
| 0.87% | |||||||
| Genmab A/S | |||||||
| 32.82 | |||||||
| 4.49 | |||||||
| 8.28 | |||||||
| 7.11% | |||||||
| $2.71 | |||||||
| $4.64 | |||||||
| 16.08% | |||||||
| Biomarin Pharmaceutical Inc | |||||||
| 125.38 | |||||||
| 3.71 | |||||||
| 7.98 | |||||||
| 0.83% | |||||||
| $0.07 | |||||||
| $0.46 | |||||||
| 15.04% | |||||||
| Incyte Corp | |||||||
| 32.93 | |||||||
| 2.81 | |||||||
| 3.87 | |||||||
| 3.54% | |||||||
| $0.26 | |||||||
| $0.86 | |||||||
| 11.63% | |||||||
| Neurocrine Biosciences Inc | |||||||
| 63.94 | |||||||
| 5.96 | |||||||
| 6.85 | |||||||
| 4.31% | |||||||
| $0.12 | |||||||
| $0.49 | |||||||
| 28.59% | |||||||
| United Therapeutics Corp | |||||||
| 13.25 | |||||||
| 1.98 | |||||||
| 5.40 | |||||||
| 4.81% | |||||||
| $0.38 | |||||||
| $0.54 | |||||||
| 18.1% | |||||||
| Exelixis Inc | |||||||
| 82.21 | |||||||
| 3.16 | |||||||
| 4.36 | |||||||
| 0.04% | |||||||
| $-0.01 | |||||||
| $0.45 | |||||||
| 14.62% | |||||||
| Average | |||||||
| 42.41 | |||||||
| 6.75 | |||||||
| 6.07 | |||||||
| 6.58% | |||||||
| $1.47 | |||||||
| $2.7 | |||||||
| 10.31% |